.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,394,408

« Back to Dashboard

Claims for Patent: 8,394,408

Title:Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Abstract: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract ("GI") of a mammal for an extended period of time.
Inventor(s): Han; Chien-Hsuan (Sunnyvale, CA), Hou; Sui Yuen Eddie (Foster City, CA), Reid; Monica L. (San Mateo, CA)
Assignee: Depomed, Inc. (Newark, CA)
Application Number:13/360,595
Patent Claims: 1. A solid oral dosage form, comprising: an immediate release portion comprising a first amount of acetaminophen, a first amount of oxycodone or a pharmaceutically acceptable salt thereof, and a disintegrant; an extended release portion comprising a polymer matrix comprising a second amount of acetaminophen and a second amount of oxycodone or salt thereof dispersed therein, said polymer matrix comprised of poly(ethylene oxide) having a molecular weight from about 900,000 to about 2,000,000 Daltons and present in an amount of about 20 to about 50 weight percent of the extended release portion; wherein the sum of the amounts of acetaminophen in the immediate release and extended release portions is about 100 to 1300 mg; and wherein the sum of the amounts of oxycodone or salt in the immediate release and extended release portions is about 5 to 40 mg.

2. The dosage form according to claim 1, wherein the dosage form releases at least 70% of the acetaminophen in the immediate release portion and at least 70% of the oxycodone or salt in the immediate release portion after about 1 hour in an in vitro dissolution test.

3. The dosage form according to claim 1, wherein the polymer matrix comprises poly(ethylene oxide) with a molecular of 900,000 Daltons in an amount of about 20 to about 50 weight percent of the extended release portion, and wherein about 20 to about 55 percent of the oxycodone is released from the extended release portion within about 1 hour in an in vitro dissolution test using a USP Disintegration Test in pH 1.2 at 37.degree. C. in 0.1 N HCl.

4. The dosage form according to claim 1, wherein the polymer matrix comprises poly(ethylene oxide) with a molecular of 2,000,000 Daltons in an amount of about 10 to about 45 weight percent of the extended release portion, and wherein about 20 to about 65 percent of the oxycodone is released from the extended release portion within about 1 hour in an in vitro dissolution test using a USP Disintegration Test in pH 1.2 at 37.degree. C. in 0.1 N HCl.

5. The dosage form according to claim 1, wherein the polymer matrix comprises poly(ethylene oxide) with a molecular of 900,000 Daltons in an amount of about 20 to about 50 weight percent of the extended release portion, and wherein about 20 to about 50 percent of the acetaminophen is released from the extended release portion within about 1 hour in an in vitro dissolution test using a USP Disintegration Test in pH 1.2 at 37.degree. C. in 0.1 N HCl.

6. The dosage form according to claim 1, wherein the polymer matrix comprises poly(ethylene oxide) with a molecular of 2,000,000 Daltons in an amount of about 10 to about 45 weight percent of the extended release portion, and wherein about 15 to about 65 percent of the acetaminophen is released from the extended release portion within about 1 hour in an in vitro dissolution test using a USP Disintegration Test in pH 1.2 at 37.degree. C. in 0.1 N HCl.

7. A solid oral dosage form, comprising: a. an immediate release portion, comprising: i. a first amount of acetaminophen; ii. a first amount of oxycodone or pharmaceutically acceptable salt thereof; iii. microcrystalline cellulose; and iv. a lubricant b. an extended release portion comprising a polymer matrix comprising: a second amount of acetaminophen; ii. a second amount oxycodone or salt thereof; iii. poly(ethylene oxide) having a molecular weight from about 900,000 to about 2,000,000 Daltons and present in an amount of about 32 to about 50 weight percent of the extended release portion; iv. microcrystalline cellulose; and v. a lubricant; wherein said second amount of acetaminophen and said second amount of oxycodone or salt thereof are dispersed in the poly(ethylene oxide), microcrystalline cellulose and lubricant; wherein the sum of the first amount of acetaminophen and second amount of acetaminophen is about 100 to 1300 mg; and wherein the sum of the first amount of oxycodone or salt thereof and second amount of oxycodone or salt thereof is about 5 to 40 mg.

8. The dosage form according to claim 7, wherein in an in vitro USP disintegration test using 800 ml 0.1 N HCl at 37.degree. C. about 40% to about 65% acetaminophen is released after 1 hour, about 55% to about 80% acetaminophen is released after 2 hours and at least about 75% acetaminophen is released after 6 hours in the test.

9. The dosage form according to claim 7, wherein in an in vitro USP disintegration test at 37.degree. C. in 0.1 N HCl about 60% oxycodone and about 50% to about 60% acetaminophen are released after 1 hour in the test.

10. The dosage form according to claim 7, wherein when administered to a dog the erosion time is about 4.00.+-.0.97 hours.

11. The dosage form according to claim 7, wherein when administered to a dog the erosion time is about 6.45.+-.1.04 hours.

12. The dosage form according to claim 7, wherein the predicted human erosion time is about 7.3.+-.1.45 hours.

13. The dosage form according to claim 7, wherein the predicted human erosion time is about 10.98.+-.1.56 hours.

14. The dosage form according to claim 7, wherein the acetaminophen comprises about 25% (w/w) of the extended release portion.

15. The dosage form according to claim 7, wherein the poly(ethylene oxide) has a molecular weight of about 900,000 Daltons.

16. The dosage form according to claim 7, wherein the poly(ethylene oxide) has a molecular weight of about 2,000,000 Daltons.

17. The dosage form according to claim 7, wherein after oral administration to a subject, oxycodone or salt thereof is released from the extended release portion at a rate proportional to release of the acetaminophen for a period of at least about 4 hours.

18. The dosage form according to claim 7, wherein the oxycodone is released from the extended release portion within about 5% to about 20% of the amount of acetaminophen released from the extended release portion over 6 hours as measured by a USP Disintegration Test with 800 mL aqueous buffer at pH 1.2 (0.1 N HCl) at 37.degree. C.

19. The dosage form according to claim 7, wherein the oxycodone is released from the extended release portion within about 5% to about 10% of the amount of acetaminophen released from the extended release portion over 6 hours as measured by a USP Disintegration Test with 800 mL aqueous buffer at pH 1.2 (0.1 N HCl) at 37.degree. C.

20. The dosage form according to claim 7, wherein the cumulative percent of oxycodone released from the extended release portion is linear when plotted as a function of square root of time for at least a period of 2 hours as measured by a USP Disintegration Test with 800 mL aqueous buffer at pH 1.2 (0.1 N HCl) at 37.degree. C.

21. A solid oral dosage form, comprising: an immediate release portion comprising a first amount of acetaminophen, a first amount of oxycodone or a pharmaceutically acceptable salt thereof, and a disintegrant; an extended release portion comprising a polymer matrix comprising a second amount of acetaminophen and a second amount of oxycodone or salt thereof dispersed therein, said polymer matrix comprised of poly(ethylene oxide) having a molecular weight from about 900,000 to about 2,000,000 Daltons and present in an amount of about 20 to about 50 weight percent of the extended release portion; wherein the sum of the first amount of acetaminophen and second amount of acetaminophen is about 100 to 1300 mg; wherein the sum of the first amount of oxycodone or salt thereof and second amount of oxycodone or salt thereof is about 5 to 40 mg; and wherein upon administration of the dosage form to a subject, erosion of the dosage form is substantially unaffected by release of the oxycodone or salt thereof.

22. The dosage form according to claim 21, wherein when administered to a dog the erosion time is about 4.00.+-.0.97 hours.

23. The dosage form according to claim 21, wherein when administered to a dog the erosion time is about 6.45.+-.1.04 hours.

24. The dosage form according to claim 21, wherein the predicted human erosion time is about 7.3.+-.1.45 hours.

25. The dosage form according to claim 21, wherein the predicted human erosion time is about 10.98.+-.1.56 hours.

26. A solid oral dosage form, comprising: a. an immediate release portion, comprising: i. a first amount of acetaminophen; ii. a first amount oxycodone or salt thereof; iii. microcrystalline cellulose; and iv. a lubricant b. an extended release portion comprising a polymer matrix comprised of: i. a second amount of acetaminophen; ii. a second amount oxycodone or salt thereof; iii. poly(ethylene oxide) having a molecular weight from about 900,000 to about 2,000,000 Daltons and present in an amount of about 32 to about 50 weight percent of the extended release portion; iv. microcrystalline cellulose; and v. a lubricant; wherein said second amount of acetaminophen and said second amount of oxycodone or salt thereof are dispersed in the poly(ethylene oxide), microcrystalline cellulose and lubricant; wherein the sum of the first amount of acetaminophen and second amount of acetaminophen is about 100 to 1300 mg; wherein the sum of the first amount of oxycodone or salt thereof and second amount of oxycodone or salt thereof is about 5 to 40 mg; and wherein in an in vitro USP disintegration test using 800 mL 0.1 N HCl at 37.degree. C. about 40% to about 65% acetaminophen is released after 1 hour, about 55% to about 80% acetaminophen is released after 2 hours and at least about 75% acetaminophen is released after 6 hours in the test.

27. The dosage form according to claim 26, wherein about 20% to about 60% oxycodone is released from the extended release portion within about 1 hour in an in vitro USP disintegration test at 37.degree. C. in 0.1 N HCl.

28. The dosage form according to claim 26, wherein in an in vitro USP disintegration test using 800 mL 0.1 N HCl at 37.degree. C. about 40% to about 65% acetaminophen is released after 1 hour, about 55% to about 80% acetaminophen is released after 2 hours and at least about 75% acetaminophen is released after 6 hours in the test.

29. The dosage form according to claim 26, wherein in an in vitro USP disintegration test at 37.degree. C. in 0.1 N HCl about 20% to about 60% acetaminophen is released from the extended release portion after 1 hour in the test.

30. The dosage form according to claim 26, wherein in an in vitro USP disintegration test at 37.degree. C. in 0.1 N HCl about 60% oxycodone and about 50% to about 60% acetaminophen are released after 1 hour in the test.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc